Element Acquires Impact Analytical

News
Article

Element’s acquisition of Impact Analytical expands their life sciences footprint in North America.

Element Material Technology announced on Sept. 2, 2021, that it has acquired Impact Analytical. This move is the latest in a series of acquisitions made by Element to expand their life sciences footprint in North America, according to a company press release.

Based in Midland, Michigan, Impact operates in the pharmaceutical, medical device, consumer product, specialty chemicals, and most recently bio-analytics segments. In particular, the company specializes in extractables and leachables.

Element’s acquisition of Impact will add various testing services to their pharmaceutical, medical device, environmental, and food segments. This is intended to complement the life science capabilities the company added with the acquisitions of ALG and Avomeen in the last twelve months, according to the press release.

“As our eighth acquisition this year and our fourth in the life sciences market, we are pleased to welcome Impact Analytical to Element,” said Rick Sluiters, executive vice-president of Americas at Element, in the press release. “With ALG and Avomeen in America and the recent announcement of our acquisition of Arch Sciences Group in Europe, Element has significantly strengthened its position in the life sciences sector.

Source: Element

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content